CSIMarket
 


Stemline Therapeutics Inc  (STML)
Other Ticker:  
 
 

STML's Income from Cont. Operations Growth by Quarter and Year

Stemline Therapeutics Inc's Income from Cont. Operations results by quarter and year




STML Income from Cont. Operations (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
IV Quarter December - -17.68 -29.51 -21.75
III Quarter September - -14.89 -21.04 -16.06
II Quarter June - -16.84 -18.93 -15.46
I Quarter March -21.29 -27.41 -18.42 -14.57
FY   -21.29 -76.82 -87.90 -67.84



STML Income from Cont. Operations first quarter 2020 Y/Y Growth Comment
Stemline Therapeutics Inc in the first quarter 2020 recorded loss from continued operations of $ -21.29 millions.

According to the results reported in the first quarter 2020, Stemline Therapeutics Inc achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Stemline Therapeutics Inc' s Income from Cont. Operations no change of % ranks overall at the positon no. in the first quarter 2020.




STML Income from Cont. Operations ( Y/Y Growth %) 2020
2019 2018 2017
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Stemline Therapeutics Inc's first quarter 2020 Income from Cont. Operations $ -21.29 millions STML's Income Statement
Stemline Therapeutics Inc's first quarter 2019 Income from Cont. Operations $ -27.41 millions Quarterly STML's Income Statement
New: More STML's historic Income from Cont. Operations Growth >>


STML Income from Cont. Operations (Quarter on Quarter Growth %)

2020
2019 2018 2017
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Stemline Therapeutics Inc's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


STML's I. Quarter Q/Q Income from Cont. Operations Comment
Recent loss from continued operations of -21.29 millions by Stemline Therapeutics Inc come out even worse compare to the loss from continued operations -17.68 millions a quarter before.

Within Major Pharmaceutical Preparations industry Stemline Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Stemline Therapeutics Inc's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


STML's I. Quarter Q/Q Income from Cont. Operations Comment
Current loss from continued operations of -21.29 millions by Stemline Therapeutics Inc come out even worse considering the -17.68 millions a quarter before.

Within Major Pharmaceutical Preparations industry Stemline Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Stemline Therapeutics Inc's Income from Cont. Operations growth quarter on quarter, overall rank is .


Stemline Therapeutics Inc's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Mar 31 2020)
12 Months Ending
(Dec 31 2019)
12 Months Ending
(Sep 30 2019)
12 Months Ending
(Jun 30 2019)
12 Months Ending
(Mar 31 2019)
Cumulative Income from Cont. Operations 12 Months Ending $ -70.70 $ -76.82 $ -88.64 $ -94.80 $ -96.89
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment


Stemline Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment


Stemline Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
STML's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for STML's Competitors
Income from Cont. Operations Growth for Stemline Therapeutics Inc's Suppliers
Income from Cont. Operations Growth for STML's Customers

You may also want to know
STML's Annual Growth Rates STML's Profitability Ratios STML's Asset Turnover Ratio STML's Dividend Growth
STML's Roe STML's Valuation Ratios STML's Financial Strength Ratios STML's Dividend Payout Ratio
STML's Roa STML's Inventory Turnover Ratio STML's Growth Rates STML's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Mar 31 2020 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Mar 31 2020
Biogen Inc -1.15%$ -1.150 millions
Baxter International Inc -4.03%$ -4.035 millions
Iradimed Corporation-4.14%$ -4.137 millions
Alexion Pharmaceuticals Inc -5.15%$ -5.154 millions
Hill rom Holdings Inc -5.25%$ -5.253 millions
Atrion Corporation-5.72%$ -5.722 millions
U s Neurosurgical Holdings Inc -5.91%$ -5.914 millions
Lifevantage Corp-6.79%$ -6.790 millions
Pra Health Sciences Inc -8.13%$ -8.125 millions
Amgen Inc -8.38%$ -8.384 millions
Charles River Laboratories International inc -8.71%$ -8.711 millions
Phibro Animal Health Corporation-9.08%$ -9.078 millions
Lemaitre Vascular Inc -9.65%$ -9.650 millions
Mettler toledo International Inc -12.24%$ -12.245 millions
Pfizer Inc-12.32%$ -12.317 millions
Encompass Health Corporation-13.44%$ -13.445 millions
Procyon Corporation-13.98%$ -13.982 millions
Haemonetics Corporation-15.41%$ -15.412 millions
Orgenesis Inc -16.98%$ -16.982 millions
Bio techne Corp-18.41%$ -18.413 millions
Abbott Laboratories-19.05%$ -19.048 millions
Carlisle Companies Incorporated-20.16%$ -20.155 millions
Bio rad Laboratories Inc -20.72%$ -20.722 millions
Gilead Sciences Inc -21.85%$ -21.850 millions
Globus Medical Inc -21.86%$ -21.864 millions
Illumina Inc -22.77%$ -22.768 millions
Catalent Inc -34.07%$ -34.069 millions
Universal Health Services Inc -39.15%$ -39.149 millions
Heartbeam Inc -39.16%$ -39.161 millions
Quest Diagnostics Inc-39.77%$ -39.773 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com